Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Biologic therapy.

Dana-Farber Cancer Institute, Boston, MA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Boston, MA
Treatments:Biologic therapyHospital:Dana-Farber Cancer Institute
Drugs:Journal:Link
Date:Aug 2014

Description:

Patients:
This study involved 12 relapsed/refractory peripheral T cell lymphoma patients. The median patient age was 70.7 years and 50% were male.

Treatment:
Patients received biologic therapy with imatinib mesylate, a tyrosine kinase inhibitor that interferes with cancer cell growth.

Toxicities:
The most severe toxicities were of grade 4 and included lymphopenia, and thrombocytopenia.

Results:
The median overall survival was 5.1 months.

Correspondence: Dr. Eric Jacobsen; email: [email protected]



Back